Erythropoietin activates two distinct signaling pathways required for the initiation and the elongation of c-myc

被引:41
作者
Chen, CM [1 ]
Sytkowski, AJ [1 ]
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med,Dept Med, Div Hematol & Oncol,Lab Cell & Mol Biol, Boston, MA 02215 USA
关键词
D O I
10.1074/jbc.M105702200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Erythropoietin (Epo) stimulation of erythroid cells results in the activation of several kinases and a rapid induction of c-myc expression. Protein kinase C is necessary for Epo up-regulation of c-myc by promoting elongation at the 3'-end of exon 1. PKC epsilon mediates this signal. We now show that Epo triggers two signaling pathways to c-myc. Epo rapidly up-regulated Myc protein in BaF3-EpoR cells. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 blocked Myc up-regulation in a concentration-dependent manner but had no effect on the Epo-induced phosphorylation of ERK1 and ERK2. LY294002 also had no effect on Epo up-regulation of c-fos. MEK1 inhibitor PD98059 blocked both the c-myc and the c-fos responses to Epo. PD98059 and the PKC inhibitor H7 also blocked the phosphorylation of ERK1 and ERK2. PD98059 but not LY294002 inhibited Epo induction of ERK1 and ERK2 phosphorylation in normal erythroid cells. LY294002 blocked transcription of c-myc at exon 1. PD98059 had no effect on transcription from exon 1 but, rather, blocked Epo-induced c-myc elongation at the 3'-end of exon 1. These results identify two Epo signaling pathways to c-myc, one of which is PI3K-dependent operating on transcriptional initiation, whereas the other is mitogen-activated protein kinase-dependent operating on elongation.
引用
收藏
页码:38518 / 38526
页数:9
相关论文
共 59 条
  • [1] PD-098059 IS A SPECIFIC INHIBITOR OF THE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE IN-VITRO AND IN-VIVO
    ALESSI, DR
    CUENDA, A
    COHEN, P
    DUDLEY, DT
    SALTIEL, AR
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (46) : 27489 - 27494
  • [2] BACON ER, 1987, BLOOD, V69, P103
  • [3] Erythropoietin activates Raf1 by an Shc-independent pathway in CTLL-EPO-R cells
    Barber, DL
    Corless, CN
    Xia, K
    Roberts, TM
    DAndrea, AD
    [J]. BLOOD, 1997, 89 (01) : 55 - 64
  • [4] A DOMINANT-NEGATIVE ERYTHROPOIETIN (EPO) RECEPTOR INHIBITS EPO-DEPENDENT GROWTH AND BLOCKS F-GP55-DEPENDENT TRANSFORMATION
    BARBER, DL
    DEMARTINO, JC
    SHOWERS, MO
    DANDREA, AD
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (04) : 2257 - 2265
  • [5] Tyrosine residues within the intracellular domain of the erythropoietin receptor mediate activation of AP-1 transcription factors
    Bergelson, S
    Klingmüller, U
    Socolovsky, M
    Hsiao, JG
    Lodish, HF
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (04) : 2396 - 2401
  • [6] Bondurant MC, 1996, J CELL PHYSIOL, V168, P255, DOI 10.1002/(SICI)1097-4652(199608)168:2<255::AID-JCP4>3.0.CO
  • [7] 2-O
  • [8] BUSFIELD SJ, 1992, BLOOD, V80, P412
  • [9] CARROLL MP, 1991, J BIOL CHEM, V266, P14964
  • [10] CARROLL MP, 1994, J BIOL CHEM, V269, P1249